HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Multimodality therapy including radiotherapy and chemotherapy improves event-free survival in stage C esthesioneuroblastoma.

AbstractBACKGROUND:
To evaluate the efficacy of multimodality therapy in patients with esthesioneuroblastoma (ENB).
PATIENTS AND METHODS:
From 01/1979 through 08/2001, 47 patients with ENB (20 men, 27 women, age 5-81 years), were registered from 18 oncologic centers. There were 14 tumors stage B and 33 stage C according to the Kadish classification. Initial treatment included surgery alone in seven patients, radiotherapy (RT) with or without chemotherapy (CTX) in twelve, surgery plus postoperative RT in 15, and multimodality therapy (surgery plus pre- or postoperative CTX plus postoperative RT) in 13.
RESULTS:
The 5-year overall survival (OS) for the whole group was 64 +/- 8% and the 5-year event-free survival (EFS) 50 +/- 8%. Patients with multimodality treatment had a significantly better 5-year EFS (74 +/- 13%) compared to the other patients (41 +/- 9%; p = 0.05), while the 5-year OS was not significantly different between the treatment groups (p = 0.39). For patients with Kadish stage C, multimodality therapy (n = 11) resulted in superior 5-year EFS (72 +/- 14% vs 17 +/- 9%; p = 0.01). These patients tended to have an improved OS (69 +/- 15% vs 47 +/- 12%; p = 0.19) compared to the other treatment groups. None of the patients with multimodality treatment had a metastatic relapse.
CONCLUSION:
Multimodality treatment (surgery plus pre- or postoperative CTX plus postoperative RT) appears to be highly efficient in preventing local and systemic relapse in patients with advanced ENB. Timing and optimal agents of CTX need to be further evaluated.
AuthorsHans Theodor Eich, Barbara Hero, Susanne Staar, Oliver Micke, Heinrich Seegenschmiedt, Adrian Mattke, Frank Berthold, Rolf-Peter Müller
JournalStrahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] (Strahlenther Onkol) Vol. 179 Issue 4 Pg. 233-40 (Apr 2003) ISSN: 0179-7158 [Print] Germany
PMID12707712 (Publication Type: Comparative Study, Journal Article)
Chemical References
  • Antineoplastic Agents
Topics
  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Antineoplastic Agents (therapeutic use)
  • Child
  • Child, Preschool
  • Combined Modality Therapy
  • Data Interpretation, Statistical
  • Disease-Free Survival
  • Esthesioneuroblastoma, Olfactory (drug therapy, mortality, radiotherapy, surgery, therapy)
  • Female
  • Humans
  • Male
  • Middle Aged
  • Nasal Cavity
  • Neoplasm Metastasis
  • Neoplasm Recurrence, Local (prevention & control)
  • Nose Neoplasms (drug therapy, mortality, radiotherapy, surgery, therapy)
  • Postoperative Care
  • Preoperative Care
  • Radiotherapy Dosage
  • Survival Analysis
  • Time Factors

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: